Highest-materiality recent filing
Oncotelic presents corporate presentation to employees; details not available in filing
Presentation given on July 13, 2026 to employees, directors, officers, and advisors.
Oncotelic grants 17,796 RSUs to executives tied to exchange uplisting by June 2027
17,796 RSUs granted to directors, officers, employees, and advisors; each RSU convertible into 1,000 common shares via Series A Preferred.
Oncotelic enters $178K convertible note financing with Pacific Pier Capital
Issued $178,410 convertible promissory note with 12% OID and 12% interest, maturing in 1 year.
Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock
Oncotelic contributed patent portfolio to Neurobridge Holdings, which merged into Lunai subsidiary; Oncotelic received 5 Series B shares (stated value $12.5M).
Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain
Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.
Oncotelic partners with TechForce Robotics to develop AI-enhanced GMP robotics platform
Joint development, manufacturing, and licensing agreement signed March 31, 2026.
Oncotelic subsidiary Sapu Nano to present everolimus tissue-toxicity data at SOT 2026
Sapu Nano (Oncotelic minority interest) to present everolimus toxicology poster at SOT 2026 in San Diego on Mar 23.
Oncotelic subsidiary Sapu Nano unveils Deciparticle platform; two Phase 1 assets at BIO-Europe
Sapu Nano to present Deciparticle platform and clinical pipeline at BIO-Europe Spring 2026 on March 25.
Oncotelic raises $358.5K via secured convertible note with Mast Hill Fund
Issued $398,333.33 convertible promissory note (10% OID, 10% interest, 1-year maturity) to Mast Hill Fund for net proceeds of ~$350K after fees.
CEO Dr. Vuong Trieu receives 4,426 preferred shares (convertible to 4.426M common) for first milestone: converting $2.175M 2023 PPM Notes into 2025 Units.
Oncotelic lowers CEO milestone threshold from $100M to $45M market cap for stock vesting
Amendment reduces first market cap milestone for CEO Vuong Trieu's restricted stock from $100M to $45M.
Oncotelic completes Tranche 3 of unit offering, raising $1.1M from 22 investors
Issued 44 units under final Tranche 3; each unit includes a $25,000 principal, 12% 2-year convertible note.
Oncotelic lowers market cap milestone for Jefferson Capital from $100M to $45M
Amendment reduces first milestone threshold in independent contractor agreement from $100M to $45M market cap.
Oncotelic closes initial $800K convertible note offering at 12% with warrants
Issued 32 units at $25,000 each to 21 accredited investors; total $800,000 raised.
Oncotelic launches PDAOAI platform and opens TGF-β corpus access
Launched PDAOAI, an evidence-interrogation platform for extracting biological signals from large datasets without training custom LLMs.
Oncotelic closes initial 11 units of up to 500-unit offering with 12% notes and warrants
Initial closing of 11 units at $25,000 each in best-efforts offering of up to 500 units.
CEO Vuong Trieu presented at LD Micro conference on Oct 21; specifics not disclosed in filing
CEO Vuong Trieu presented a corporate presentation at LD Micro in San Diego on October 21, 2025.
Engaged Jefferson Capital Ventures and Valor Nation for 18-month consulting and advisory services starting August 6, 2025.
Oncotelic secures $560K convertible note from Mast Hill; enters $25M equity purchase agreement
Issued $560,000 convertible promissory note to Mast Hill Fund, 10% OID, 10% interest, convertible at $0.07/share.
Phase 1 trial (NCT04862767) of OT-101 + IL-2 in advanced solid tumors shows tolerable safety, no unexpected signals.
Oncotelic extends reverse merger deadline with Mosaic ImmunoEngineering to June 30, 2025
Term sheet dated April 26, 2024, originally 90-day term, extended to Dec 31, 2024; now extended to June 30, 2025.
Oncotelic sells necroptosis cancer therapy assets to Mosaic for up to $30M
Mosaic to issue $15M in shares at closing; Oncotelic may earn $15M more in cash/shares based on milestones.
Oncotelic completes $0.5M debt conversion and issues 12 convertible note units
Issued 12 units each with a $25,000 convertible note (convertible at $0.10/share) and warrants to buy 250,000 shares at $0.12/share.
Oncotelic closes 3rd tranche of unit financing, raising $1.05M via convertible notes and warrants
42 units issued at $25,000 each for aggregate $1.05M; each unit includes a convertible note and 250,000 warrants.
Oncotelic JV Sapu starts registrational Phase 2b/3 trial of OT-101 in pancreatic cancer
Sapu Bioscience (Oncotelic 45% JV partner) signed master services agreement with Cromos Pharma for OT-101 registrational trial.
Oncotelic closes $1.0M debt-to-equity conversion; issues 40 Units with notes and warrants
Converted $1.0M of debt via private placement of 40 Units to accredited investors.
Oncotelic adopts new bylaws with advance notice provisions for shareholder proposals.
Board adopted new amended and restated bylaws on May 18, 2023.
Publication in Cancers shows high intra-tumor TGF-β2 level predicts poor survival in pediatric brainstem cancer (DIPG).
Oncotelic CMO Fatih Uckun resigns; CRO Seymour Fein assumes CMO role
Fatih Uckun, MD, PhD, resigned as Chief Medical Officer effective February 28, 2023.
Oncotelic details 2023 pipeline: 10+ OT-101 trials, pancreatic & glioma FPI, BARDA award
At least 10 investigator-initiated OT-101 trials planned in 2023 for NSCLC, pancreatic, melanoma, gliomas.
Oncotelic presents clinical data confirming TGF-β2 as target for gliomas; OS improvements shown
Reduced TGF-β2 increased OS from 9 to 22 mos in pediatric brainstem patients (N=95, p<0.0001).
55% of OT-101-treated pancreatic cancer patients had long-term disease control (21 of 37 pts).
Oncotelic issues $335K convertible note to Blue Lake Partners as part of $1M financing
Issued $335,000 convertible promissory note to Blue Lake Partners, LLC at 12% interest.
Oncotelic discloses JV IPO target and OT-101 COVID mortality data at BIO2022
JVCo IPO on track for 2023 with anticipated minimum valuation of $200M, range $1-5B.
Oncotelic issues $605K convertible note to Mast Hill; uses up to $250K to repay prior debt
Issued $605,000 convertible promissory note to Mast Hill Fund, LP at 12% interest, convertible at $0.10 per share.
Oncotelic appoints CMO Fatih Uckun and CRO Seymour Fein effective May 1, 2022
Fatih Uckun appointed Consulting CMO; $504k/year salary, 70% time commitment.
Oncotelic contributed global, exclusive, perpetual, royalty-free license of OT-101 IP for 45% ownership in JV.
Oncotelic forms joint venture with Dragon Overseas; Dragon to invest $27.6M for 55% stake
Dragon Overseas invests $27.6M in cash and assets for 55% of JV; Oncotelic contributes OT-101 licenses for 45%.
Oncotelic issues $0.25M convertible note to Fourth Man, LLC at 12% interest
Convertible promissory note principal $0.25M, 12% annual interest, matures in one year.
Oncotelic announces JV agreement signing, press release and 8-K forthcoming
Presented at MedInvest Pharmaceutical and Biotechnology Investor Conference on March 31, 2022.
Oncotelic extends JV term sheet standstill with GMP to March 31, 2022
Extended standstill provisions of JV term sheet with Golden Mountain Partners to March 31, 2022.
Oncotelic extends JH Darbie note maturity to Mar 2023; issues 33M warrants at $0.15
Maturity of convertible notes extended from March 31, 2022 to March 31, 2023 with all but one investor agreeing.
Oncotelic launches new OT-101 corporate presentation; JV re-IPO funding on track
New corporate presentation deployed Feb 7, 2022, covering OT-101 therapeutic programs.
Oncotelic issues $0.5M convertible note to Golden Mountain Partners as part of $1.5M funding
Issued $0.5M unsecured convertible note to Golden Mountain Partners, part of up to $1.5M total in three monthly installments.
Oncotelic updates on OT-101 biomarker program pursuing accelerated approval route for solid tumors
New corporate presentation highlights OT-101 biomarker program with pembrolizumab in multiple phase 2 trials.
Oncotelic Therapeutics dismisses Baker Tilly, hires Rose Snyder & Jacobs as auditor
Baker Tilly's reports for FY 2020 and 2019 contained a going-concern emphasis paragraph.
Oncotelic issues $0.75M in convertible notes at $0.07/sh; repays $307.5K Geneva Notes
Issued three convertible notes on Dec 9, 12, 15, 2021 totaling $0.75M gross; part of a $1.25M financing round.
Oncotelic issues $0.5M in convertible notes at $0.07/share to repay existing debt
Issued two convertible notes: $0.25M to Talos Victory Fund and $0.25M to Mast Hill Fund.
Oncotelic reports Q3 net loss of $1.9M; provides JV, license, and clinical updates
Net loss: $1.86M (($0.00)/share) vs $1.99M (($0.02)/share) in Q3 2020; operating expenses rose to $1.8M.
Oncotelic reports positive Phase 2 COVID-19 data: 3X survival benefit for critical patients
Safety endpoints met; OT-101 was safe in severe/critical COVID-19 patients.
On February 28, 2023, Fatih Uckun, MD, Ph. D, Chief Medical Officer (“ CMO ”) of Oncotelic Therapeutics, Inc. (the “ Company ”), notified the Company of his resignation as the Company’s CMO, effective February 28, 2023.
Dr. Seymour Fein MD, Chief Regulatory Officer (“CRO”) of the Company, will be taking over the CMO role.
On May 1, 2022, Oncotelic Therapeutics, Inc. (the “ Company ”) appointed Fatih Uckun, M.D., Ph.D. as its Consulting Chief Medical Officer for the Company.
In addition, on May 1, 2022, the Company appointed Dr. Seymour Fein as its Consulting Chief Regulatory Officer.
On July 16, 2021, David Diamond notified the Board of Directors (the “ Board ”) of Oncotelic Therapeutics, Inc. (the “ Company ”) of his decision to resign, effective immediately, from his position as a member of the Board.
On July 1, 2021, Chulho Park, Ph. D., provided notice to the Company of his intention to resign as the Chief Technology Officer of the Company, to be effective immediately.
Max materiality 0.90 · Median 0.55 · Most common event other_material